Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methacrylic Acid SCHEMBL20606702 | 1.00 | TDP1 (0.42) | TDP1FFAR3LCKFYNALDH1A1 | |
| Methacrylic Acid SCHEMBL20606678 | 1.00 | TDP1 (0.42) | TDP1FFAR3LCKFYNALDH1A1 | |
| Methacrylic Acid SCHEMBL5477363 | 0.97 | TDP1 (0.40) | TDP1FFAR3LCKFYNALDH1A1 | |
| Methacrylic Acid SCHEMBL21777198 | 0.91 | TDP1 (0.50) | TDP1FFAR3LCKFYNALDH1A1 | |
| Methacrylic Acid SCHEMBL1024582 | 0.89 | — | — | |
| Methacrylic Acid SCHEMBL10706979 | 0.89 | — | — | |
| Methacrylic Acid SCHEMBL28832467 | 0.89 | TDP1 (0.50) | TDP1FFAR3LCKFYNALDH1A1 | |
| Methacrylic Acid SCHEMBL2721277 | 0.89 | TDP1 (0.35) | TDP1FFAR3LCKFYNALDH1A1 | |
| Methacrylic Acid SCHEMBL13234423 | 0.86 | — | — | |
| Methacrylic Acid SCHEMBL11235035 | 0.86 | TDP1 (0.53) | TDP1FFAR3LCKFYNALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240042093-A1 | IN SITU SOLIDIFYING INJECTABLE COMPOSITIONS WITH TRANSIENT CONTRAST AGENTS AND METHODS OF MAKING AND USING THEREOF | MERIT MEDICAL SYSTEMS, INC. | 2024-02-08 | — | — | US | claimed |
| EP-4267201-A1 | IN SITUSOLIDIFYING INJECTABLE COMPOSITIONS WITH TRANSIENT CONTRAST AGENTS AND METHODS OF MAKING AND USING THEREOF | Fluidx Medical Technology, LLC (US) | 2023-11-01 | — | — | EP | claimed |
| US-20230056283-A1 | IN SITU SOLIDIFYING SOLUTIONS AND METHODS OF MAKING AND USING THEREOF | MERIT MEDICAL SYSTEMS, INC. | 2023-02-23 | — | — | US | claimed |
| WO-2022140513-A1 | IN SITU SOLIDIFYING INJECTABLE COMPOSITIONS WITH TRANSIENT CONTRAST AGENTS AND METHODS OF MAKING AND USING THEREOF | FLUIDX MEDICAL TECHNOLOGY, LLC (US) | 2022-06-30 | — | — | WO | claimed |
| US-20200324017-A1 | IN SITU SOLIDIFYING SOLUTIONS AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2020-10-15 | — | — | US | claimed |
| US-10729807-B2 | In situ solidifying solutions and methods of making and using thereof | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2020-08-04 | — | — | US | claimed |
| US-20190321510-A1 | IN SITU SOLIDIFYING HOMOGENEOUS SOLUTIONS AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2019-10-24 | — | — | US | claimed |
| US-10369249-B2 | In situ solidifying complex coacervates and methods of making and using thereof | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2019-08-06 | — | — | US | claimed |
| CN-109705681-A | A kind of new-energy automobile environment-friendly water-based paint and preparation method thereof | 杨记周 | 2019-05-03 | — | — | CN | claimed |
| US-20180256776-A1 | IN SITU SOLIDIFYING COMPLEX COACERVATES AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2018-09-13 | — | — | US | claimed |
| US-9913927-B2 | In situ solidifying complex coacervates and methods of making and using thereof | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2018-03-13 | — | — | US | claimed |
| EP-4506429-A2 | PRETREATMENT COMPOSITIONS BONDED TO METAL SUBSTRATES AND METHODS OF MAKING THE SAME | Novelis Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119081499-A | Pretreatment composition bonded to metal substrate and method for preparing the same | 诺维尔里斯公司 | 2024-12-06 | — | — | CN | disclosed |
| EP-4165135-B1 | PRETREATMENT COMPOSITIONS BONDED TO METAL SUBSTRATES AND METHODS OF MAKING THE SAME | NOVELIS INC (US) | 2024-11-27 | — | — | EP | disclosed |
| US-20240042093-A1 | IN SITU SOLIDIFYING INJECTABLE COMPOSITIONS WITH TRANSIENT CONTRAST AGENTS AND METHODS OF MAKING AND USING THEREOF | MERIT MEDICAL SYSTEMS, INC. | 2024-02-08 | — | — | US | disclosed |
| CN-101321788-A | Use and application of specified zwitterionic copolymers | PROCTER & GAMBLE (US) | 2008-12-10 | — | — | CN | disclosed |
| CN-101247785-A | Cosmetic composition containing an amholyte copolymer | RHONE POULENC CHIMIE (FR) | 2008-08-20 | — | — | CN | disclosed |
| CN-1897913-A | Cosmetic composition comprising an amphoteric copolymer | RHODIA CHIMIE SA (FR) | 2007-01-17 | — | — | CN | disclosed |
| CN-1705562-A | Flame retardant composition | DURFACE SPECIAL TIES S A (BE) | 2005-12-07 | — | — | CN | disclosed |
| CN-1167788-A | Dual-cure latex compositions | ROHM & HAAS (US) | 1997-12-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180256776-A1 | IN SITU SOLIDIFYING COMPLEX COACERVATES AND METHODS OF MAKING AND USING THEREOF | EPCAM, SELE, ILK | TDP1 3874/4885FFAR3 2797/4885LCK 2433/4885 |
| US-20190321510-A1 | IN SITU SOLIDIFYING HOMOGENEOUS SOLUTIONS AND METHODS OF MAKING AND USING THEREOF | VCL, F12, SELE | TDP1 3307/4885FFAR3 2192/4885LCK 1668/4885 |
| US-10369249-B2 | In situ solidifying complex coacervates and methods of making and using thereof | EPCAM, SELE, ILK | TDP1 3874/4885FFAR3 2797/4885LCK 2433/4885 |
| US-20230056283-A1 | IN SITU SOLIDIFYING SOLUTIONS AND METHODS OF MAKING AND USING THEREOF | VCL, ILK, SELE | TDP1 3372/4885FFAR3 2456/4885LCK 1949/4885 |
| US-20200324017-A1 | IN SITU SOLIDIFYING SOLUTIONS AND METHODS OF MAKING AND USING THEREOF | VCL, ILK, SELE | TDP1 3372/4885FFAR3 2456/4885LCK 1949/4885 |
| US-10729807-B2 | In situ solidifying solutions and methods of making and using thereof | VCL, ILK, SELE | TDP1 3372/4885FFAR3 2456/4885LCK 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.